[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Data are presented on a randomized study (stage II) which was undertaken to assess the efficacy of neoadjuvant chemotherapy (doxorubicin+paclitaxel) vis-a-vis endocrine therapy with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive tumors. Preoperative neoadjuvant chemotherapy was well tolerated and showed similar rates of overall response as compared with the latter regimen.
Semiglazov
V F
VF
Semiglazov
V V
VV
Dashian
G A
GA
Zhil'tsova
E K
EK
Ivanov
V G
VG
Bozhok
A A
AA
Tonuzov
E E
EE
Paltuev
R M
RM
Mel'nikova
O A
OA
Klettsel'
A A
AA
Krivorot'ko
P V
PV
Donskikh
R V
RV
Kochetova
I A
IA
Damenia
A O
AO
Zernov
K Iu
KIu
Voskresenskiĭ
D A
DA
Bershteĭn
L M
LM
D000368:Aged; D000369:Aged, 80 and over; D000077384:Anastrozole; D000730:Androstadienes / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009570:Nitriles / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D014230:Triazoles; D000077384:Anastrozole; D004317:Doxorubicin; C056516:exemestane; D017239:Paclitaxel